# Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

> **NCT04672434** · PHASE1 · COMPLETED · sponsor: **Symphogen A/S** · enrollment: 48 (actual)

## Conditions studied

- Metastatic Cancer
- Solid Tumor

## Interventions

- **DRUG:** Sym021
- **DRUG:** Sym024

## Key facts

- **NCT ID:** NCT04672434
- **Lead sponsor:** Symphogen A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-19
- **Primary completion:** 2024-11-22
- **Final completion:** 2024-11-22
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04672434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04672434, "Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04672434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*